Novartis’ mAb could become first Sjögren’s disease drug after Phase III success
If approved, ianalumab would become the first targeted treatment for patients with Sjögren’s disease.
12 August 2025
12 August 2025
If approved, ianalumab would become the first targeted treatment for patients with Sjögren’s disease.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.